Physician profile
Brian J Larkin
NPI 1598976490
$5,457.29
in general payments reported to CMS, 2019-2025
14 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $115 · 2021: $311 · 2022: $396 · 2023: $1,127 · 2024: $1,540 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,020 · Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,020.00 |
| Food and Beverage | $510.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $4,726.53 | 2021-2025 | Persona, Tapestry, Mymobility Platform |
| Medacta USA, INC. | $303.20 | 2020-2021 | |
| Stryker Corporation | $103.15 | 2019-2021 | |
| Bsn Medical INC | $76.75 | 2023 | |
| Depuy Synthes Sales INC. | $49.43 | 2023-2024 | Monovisc, Orthovisc, Na |
| Smith+Nephew, INC. | $42.13 | 2020 | |
| Boston Scientific Corporation | $36.11 | 2025 | Wavewriter Alpha Prime 16 |
| Biotissue Holdings INC. | $18.55 | 2025 | |
| Bioventus LLC | $18.36 | 2021 | |
| Innovation Technologies INC | $18.09 | 2024 | Irrisept |
| Fidia Pharma USA INC. | $17.38 | 2024 | Hymovis, Triluron, Hyalgan |
| Sanofi-Aventis U.S. LLC | $16.30 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2019 | |
| Avanos Medical | $15.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.